Christopher Alexander
Nurse Practitioner · Baton Rouge, LANPI 1013149954
Payments from drug & device makers
Across 238 payments — averaging $23.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$824
- Amgen$572
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$474
- Novartis$408
- AstraZeneca$385
- Medtronic$378
- plus $3K from 32 others
What the payments were for
- Food & beverage$5,562100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 32 | $824 |
| Amgen | 16 | $572 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 18 | $474 |
| Novartis | 36 | $408 |
| AstraZeneca | 9 | $385 |
| Medtronic | 5 | $378 |
| Kestra Medical Technology Services, Inc. | 18 | $339 |
| Johnson & Johnson | 21 | $324 |
| Merck | 15 | $234 |
| Bard Peripheral Vascular, Inc. | 1 | $160 |
| Endologix LLC | 1 | $148 |
| Pfizer | 7 | $142 |
| E.r. Squibb & Sons, L.L.C. | 9 | $141 |
| Boehringer Ingelheim | 7 | $128 |
| Scpharmaceuticals Inc. | 6 | $100 |
| Terumo Medical Corporation | 1 | $92 |
| Abiomed | 3 | $61 |
| Alnylam Pharmaceuticals Inc. | 2 | $56 |
| Cvrx, Inc. | 2 | $55 |
| Lexicon Pharmaceuticals, Inc. | 3 | $52 |
| Cardiac Dimensions, Inc. | 1 | $51 |
| Boston Scientific | 2 | $47 |
| Amarin Pharma, Inc. | 3 | $46 |
| Bayer | 2 | $42 |
| Novo Nordisk | 2 | $39 |
| Arbor Pharmaceuticals, Inc. | 3 | $38 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| GE HealthCare | 1 | $26 |
| Janssen Scientific Affairs, LLC | 1 | $24 |
| Astellas Pharma US Inc | 1 | $24 |
| Convatec Inc. | 1 | $22 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $21 |
| Lilly USA, LLC | 1 | $20 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $18 |
| Chiesi USA, Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Inspire Medical Systems, Inc. | 1 | $15 |
| Itamar Medical Inc | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$312
- Repatha$241
- SYMPLICITY G3$172
- ESPRIT$164
- VENOVO$160
- Torus Stent Graft System$148
- ENDOCROSS Device$148
- 3F$137
- MitraClip$112
- AVEIR$107
How this compares
$5,576 in reported general payments places this provider in the 90th percentile of 969 nurse practitioner providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 126 | $137,567 |
| EntrestoSacubitril/Valsartan | 93 | $99,872 |
| Repatha SureclickEvolocumab | 96 | $65,047 |
| XareltoRivaroxaban | 30 | $27,817 |
| JardianceEmpagliflozin | 19 | $15,057 |
| BrilintaTicagrelor | 19 | $14,158 |
| LivaloPitavastatin Calcium | 15 | $6,627 |
| Nebivolol Hcl | 64 | $3,705 |
| Ranolazine ErRanolazine | 43 | $3,387 |
| Atorvastatin Calcium | 415 | $3,276 |
| Metoprolol Succinate | 237 | $2,820 |
| Rosuvastatin Calcium | 196 | $2,430 |
| Hydralazine Hcl | 106 | $1,987 |
| ClopidogrelClopidogrel Bisulfate | 230 | $1,849 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 43 | $1,849 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $142 | $137,567126 claims |
| NovartisEntresto | $408 | $99,87293 claims |
| Johnson & JohnsonXarelto | $324 | $27,81730 claims |
| Boehringer IngelheimJardiance | $128 | $15,05719 claims |
| AstraZenecaBrilinta | $385 | $14,15819 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $27 | $6,62715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 969 nurse practitioner providers in Louisiana.
Other nurse practitioner in Baton Rouge
- Sara FrankBaton Rouge$14K
- Jasmine SpearmanBaton Rouge$13K
- Morgan HoffmanBaton Rouge$12K
- Breanna ByrdBaton Rouge$9K
- Ashley AmedeeBaton Rouge$9K
- Judson JonesBaton Rouge$9K
- Emily Santa AnaBaton Rouge$7K
- Allyson DupreBaton Rouge$7K
- Karen DeshotelLafayette$264K
- Christopher ManuelKaplan$145K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.